PAI-1 Inhibitor

PAI-1 Inhibitors (28):

Cat. No.	Product Name	Effect	Purity

HY-15253

Tiplaxtinin	Inhibitor	98.78%
Tiplaxtinin is a selective and orally efficacious inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC₅₀ of 2.7 μM.

HY-101761

TM5441	Inhibitor	98.32%
TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1), has IC₅₀ values between 13.9 and 51.1 μM and induces intrinsic apoptosis in several human cancer cell lines. TM5441 attenuates Nω-nitro-l-arginine methyl ester-induced cardiac hypertension and vascular senescence.

HY-P2230

Angstrom6	Inhibitor	99.01%
Angstrom6 (A6 Peptide) is an 8 amino-acid peptide derived from single-chain urokinase plasminogen activator (scuPA) and interferes with the uPA/uPAR cascade and abrogates downstream effects. Angstrom6 binds to CD44 resulting in the inhibition of migration, invasion, and metastasis of tumor cells, and the modulation of CD44-mediated cell signaling.

HY-100447

TM5275 sodium	Inhibitor	98.99%
TM5275 sodium is a plasminogen activator inhibitor (PAI-1) with an IC₅₀ of 6.95 μM.

HY-N1504R

Loureirin B (Standard)	Inhibitor
Loureirin B (Standard) is the analytical standard of Loureirin B. This product is intended for research and analytical applications. Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC₅₀ of 26.10 μM; Loureirin B also inhibits KATP, the phosphorylation of ERK and JNK, and has anti-diabetic activity.

HY-122542A

PPACK dihydrochloride	Inhibitor
PPACK dihydrochloride is a plasminogen activator (rt-PA) inhibitor. PPACK dihydrochloride can inhibit changes in fibrin degradation products, plasminogen and alpha 2-antiplasmin. PPACK dihydrochloride also inhibits the binding of rt-PA to plasma protease inhibitors.

HY-124577

MDI-2268	Inhibitor
MDI-2268 is an inhibitor of plasma kallikrein inhibitor 1 (PAI-1). MDI-2268 has good antithrombotic properties and regulates blood coagulation and fibrinolysis process by enhancing fibrinolysis. MDI-2268 can be used in research areas such as deep vein thrombosis.

HY-100415

UKI-1	Inhibitor
UKI-1 (WX-UK1) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a K_i of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells.

HY-14759

Aleplasinin	Inhibitor	99.26%
Aleplasinin is an orally active, potent, BBB-penetrated and selectiveSERPINE1 (PAI-1, Plasminogen activator inhibitor-1) inhibitor. Aleplasinin increases amyloid-β (Aβ) catabolism and ameliorates amyloid-related pathology. Aleplasinin improves memory deficiency. Aleplasinin can be used for Alzheimer's disease research.

HY-101214

UK-371804	Inhibitor	≥98.0%
UK-371804 is a urokinase-type plasminogen activator (uPA) inhibitor with a K_i of 10 nM.

HY-122542B

PPACK TFA	Inhibitor	99.28%
PPACK TFA is a plasminogen activator (rt-PA) inhibitor. PPACK TFA can inhibit changes in fibrin degradation products, plasminogen and alpha 2-antiplasmin. PPACK TFA also inhibits the binding of rt-PA to plasma protease inhibitors.

HY-120516

CDE-096	Inhibitor	99.97%
CDE-096 is a potent inhibitor of PAI-1. CDE-096 prevents PAI-1 from inactivating tPA and uPA with similar potency (IC₅₀=30 and 25 nM, respectively) and is active against glycosylated PAI-1, as well as PAI-1 derived from several species (IC₅₀=19, 22 and 18 nM for murine, rat, and Porcine PAI-1, respectively).

HY-122098

Diaplasinin	Inhibitor	99.97%
Diaplasinin (PAI-749) is a plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC₅₀ of 295 nM. Diaplasinin has antithrombotic efficacy.

HY-N0518

Toddalolactone	Inhibitor	99.97%
Toddalolactone, a main component of Toddalia asiatica, inhibits the activity of recombinant human plasminogen activator inhibitor-1 (PAI-1), with an IC₅₀ value of 37.31 μM.

HY-N1504

Loureirin B	Inhibitor	99.16%
Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC₅₀ of 26.10?μM; Loureirin B also inhibits K_ATP, the phosphorylation of ERK and JNK, and has anti-diabetic activity.

HY-114330A

ZK824859 hydrochloride	Inhibitor	99.03%
ZK824859 hydrochloride is an oral available and selective urokinase plasminogen activator (uPA) inhibitor with IC₅₀s of 79 nM, 1580 nM and 1330 nM for human uPA, tPA, and plasmin, respectively.

HY-108447

BC-11 hydrobromide	Inhibitor	≥99.0%
BC-11 hydrobromide is a selective TMPRSS2 inhibitor (TMPRSS2 is a key host cellular factor for viral entry and SARS-CoV-2 pathogenesis), and a selective urokinase (uPA) inhibitor (IC₅₀=8.2 μM). BC-11 hydrobromide is cytotoxic to triple-negative MDA-MB231 breast cancer cells. BC-11 hydrobromide is used in research on viral infections and cancer.

HY-122714

SK-216	Inhibitor
SK-216 is a plasminogen activator inhibitor-1 (PAI-1) inhibitor that acts as an anti-metastatic agent for human osteosarcoma and inhibits lung metastasis of human osteosarcoma.

HY-117724

AZ3976	Inhibitor	98.03%
AZ3976 is a potent plasminogen activator inhibitor type 1 (PAI-1) inhibitor with an IC₅₀ value of 26 μM in an enzymatic chromogenic assay. AZ3976 is active with an IC₅₀ of 16 μM in a plasma clot lysis assay. AZ3976 does not bind to active PAI-1 but bound reversibly to latent PAI-1. AZ3976 inhibits PAI-1 by enhancing the latency transition of active PAI-1. AZ3976 displays profibrinolytic activities in a human plasma clot lysis assay.

HY-117359

UCD38B hydrochloride	Inhibitor	99.31%
UCD38B hydrochloride is a cell permeant, competitive enzymatic uPA inhibitor with an IC₅₀ value of 7 μM. UCD38B hydrochloride targets intracellular uPA causing mistrafficking of uPA into perinuclear mitochondria, reducing the mitochondrial membrane potential, and followed by the release of apoptotic inducible factor (AIF). UCD38B hydrochloride induces apoptosis.

Name
Email *

	Sorry, but the email address you supplied was invalid.